On March 2, the reporter learned from the relevant departments that 700,000 recombinant novel coronavirus protein vaccines (CHO cells) have arrived in Guangdong.
According to the unified deployment of the state, provinces and municipalities, Guangdong Province will launch a sequential strengthening of immunization in the near future, that is, the target population that completes the full vaccination of the inactivated vaccine of Sinopharm Zhongsheng Beijing Company, Wuhan Company and Beijing Kexing Company can choose the recombinant protein vaccine of Zhifeilong Koma or the adenovirus vector vaccine of CanSino to carry out 1 dose of sequential enhanced immunization, which provides a new means for the establishment of the original immune barrier and makes the immune barrier more solid and durable.
The first to be approved
Domestic recombinant new coronavirus protein vaccine was launched
It is reported that on March 1, the State Drug Administration conditionally approved the application for the listing and registration of the recombinant novel coronavirus protein vaccine (CHO cells) of Anhui Zhifeilong Kema Biopharmaceutical Co., Ltd. The vaccine is the first approved domestic recombinant COVID-19 protein vaccine for the prevention of diseases caused by novel coronavirus infection (COVID-19).
In accordance with the relevant provisions of the Vaccine Administration Law and the Drug Administration Law, the State Food and Drug Administration conducts emergency review and approval in accordance with the special approval procedures for drugs, and conditionally approves the application for market registration of the vaccine. The State Food and Drug Administration requires the holder of the marketing authorization of the vaccine to continue to carry out relevant research work, complete the conditional requirements, and submit the follow-up research results in a timely manner.
92.87% effective against critical care
According to the reporter's understanding, the recombinant novel coronavirus protein vaccine (CHO cells) jointly developed by the Institute of Microbiology of the Chinese Academy of Sciences and Anhui Zhifei Longkema Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of Zhifei Biology, as of June 30, 2021, the preliminary analysis results of the overseas Phase III clinical trial data show that after 7 days of three doses of vaccination, the vaccine has a protective effect of 81.43% (95% on people aged 18 and above (the total population) to prevent any severity of COVID-19. The confidence interval is 73.35% to 87.38%); the protective efficacy for severe cases of COVID-19 and above is 92.87%.
The results of the analysis of the variant strains showed that the protective efficacy of the Delta strains after 7 days of inoculation was 81.38%. The results of the vaccine protection efficacy data met the relevant technical standards of the World Health Organization and the relevant standards in the "Guidelines for clinical evaluation of vaccines for the prevention of novel coronavirus (trial)" issued by the State Drug Administration.
700,000 domestically produced recombinant COVID-19 protein vaccines
Arrived in Guangdong
According to the news released by the National Health Commission on February 19, China has begun to deploy sequential enhanced immunization, of which after the implementation of the sequential strengthening immunization strategy, the target population that completes the inactivated vaccine of Sinopharm Zhongsheng Beijing Company, Wuhan Company and Beijing Kexing Company can also choose the recombinant protein vaccine of Zhifeilong Koma or the adenovirus vector vaccine of CanSino to carry out 1 dose of sequential enhanced immunization.
On March 2, the reporter learned from relevant parties that 700,000 recombinant novel coronavirus protein vaccines (CHO cells) that have just been approved for marketing have arrived in Guangdong, and the prelude to the sequential strengthening of immunization will begin.
Source | Yangcheng Evening News, Golden Sheep Network, Yangcheng Pie
Textu | Yangcheng Evening News all-media reporter Zhang Hua
Edit | Wooden words
Proofreading | Zhu Xiaoming
Review and sign | Zhou Lerui